| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1041103687 |
| P356 | DOI | 10.1186/S13045-015-0155-Z |
| P932 | PMC publication ID | 4469402 |
| P698 | PubMed publication ID | 26022204 |
| P5875 | ResearchGate publication ID | 277408446 |
| P50 | author | Filip Janku | Q73569186 |
| Hyunseon Kang | Q42768103 | ||
| P2093 | author name string | Robert A Wolff | |
| Sunil Krishnan | |||
| Lopa Mishra | |||
| Mingxin Zuo | |||
| Milind Javle | |||
| Ahmed O Kaseb | |||
| Abby B Siegel | |||
| Melanie B Thomas | |||
| Rachna Shroff | |||
| Christian Barrera | |||
| Chaitanya Churi | |||
| Humaid Alshamsi | |||
| Rakesh Surapaneni | |||
| P2860 | cites work | Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 | Q24321567 |
| HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies | Q26822730 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 | ||
| Activating HER2 mutations in HER2 gene amplification negative breast cancer | Q27851987 | ||
| Shc products are substrates of erbB-2 kinase | Q28678747 | ||
| Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing | Q29614576 | ||
| Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer | Q33557258 | ||
| Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma | Q33814916 | ||
| Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review | Q34631121 | ||
| Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications | Q34764681 | ||
| Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies | Q35022847 | ||
| The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis. | Q51076395 | ||
| Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. | Q53149260 | ||
| Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients. | Q53577314 | ||
| Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. | Q54483761 | ||
| [HER2 and gastric cancer. Recommendations for clinical practice in 2011]. | Q54588327 | ||
| Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 | ||
| Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases | Q83770969 | ||
| FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma | Q35588892 | ||
| Molecular characterization of gallbladder cancer using somatic mutation profiling | Q35597012 | ||
| HER2: biology, detection, and clinical implications | Q35622862 | ||
| Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? | Q35863874 | ||
| Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma | Q36614705 | ||
| HER2-positive gastric cancer | Q37468290 | ||
| Whole cancer genome sequencing by next-generation methods | Q37932206 | ||
| Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry | Q38456543 | ||
| Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway | Q38977752 | ||
| Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure | Q39580861 | ||
| Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab | Q42033747 | ||
| Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma | Q44860005 | ||
| Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder | Q46447600 | ||
| Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers | Q46488823 | ||
| Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics | Q48337801 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 58 | |
| P577 | publication date | 2015-05-29 | |
| P1433 | published in | Journal of Hematology & Oncology | Q15724593 |
| P1476 | title | HER2/neu-directed therapy for biliary tract cancer | |
| P478 | volume | 8 |
| Q92621615 | A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells |
| Q89887782 | Applied precision cancer medicine in metastatic biliary tract cancer |
| Q39396785 | Biliary cancer: Utility of next-generation sequencing for clinical management |
| Q39289707 | Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications |
| Q92684142 | Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study |
| Q41431886 | Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. |
| Q88923207 | Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention |
| Q92593276 | Comprehensive molecular profiling of extrahepatic cholangiocarcinoma in Chinese population and potential targets for clinical practice |
| Q92591396 | Contemporary Tailored Oncology Treatment of Biliary Tract Cancers |
| Q38830071 | Current Progress in Immunotherapy for the Treatment of Biliary Cancers |
| Q47103332 | Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment |
| Q57284115 | ERBB2 and KRAS Alterations Mediate Response to EGFR Inhibitors in Early Stage Gallbladder Cancer |
| Q52668202 | Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. |
| Q57298169 | Emerging role of precision medicine in biliary tract cancers |
| Q90319038 | Gallbladder cancer harboring ERBB2 mutation on the primary and metastatic site: A case report |
| Q55481891 | Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico. |
| Q98159763 | Genetic analysis in the clinical management of biliary tract cancer |
| Q34540948 | Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice |
| Q37017110 | Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design |
| Q50127508 | Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers. |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q90242172 | HER2-targeted therapies - a role beyond breast cancer |
| Q39040859 | HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? |
| Q34553167 | Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells |
| Q93010677 | Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures |
| Q92251015 | Landscape of distant metastasis mode and current chemotherapy efficacy of the advanced biliary tract cancer in the United States, 2010-2016 |
| Q40421102 | Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients |
| Q91872582 | Long term recurrence free survival in a stage IV gallbladder cancer treated with chemotherapy plus trastuzumab and salvage liver resection |
| Q92486872 | Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets |
| Q28072275 | Molecular profiling of biliary tract cancer: a target rich disease |
| Q92029922 | Molecular targets in cholangiocarcinoma |
| Q90308323 | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma |
| Q54476966 | New molecular and immunotherapeutic approaches in biliary cancer. |
| Q38799963 | Novel investigational therapies for treating biliary tract carcinoma |
| Q92716614 | Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers |
| Q38653309 | Pertuzumab in gastrointestinal cancer |
| Q91646711 | Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer |
| Q64082699 | Profiling of gallbladder carcinoma reveals distinct miRNA profiles and activation of STAT1 by the tumor suppressive miRNA-145-5p |
| Q92460033 | Second-line therapies in advanced biliary tract cancers |
| Q92593269 | Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients |
| Q40327923 | Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes |
| Q64249982 | Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials |
| Q26798443 | Targeted Therapy in Biliary Tract Cancers |
| Q30234532 | Targeted therapy in biliary tract cancers-current limitations and potentials in the future |
| Q89533973 | Targeting gallbladder cancer: a pathway based perspective |
| Q33656860 | The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer |
| Q37628969 | Therapeutic implication of HER2 in advanced biliary tract cancer |
| Q79416300 | Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma |
Search more.